Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for ...

Kenvue Inc . (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson in 2023, finds itself at a critical juncture as it navigates its first full year as an independent entity. The ...

Aid, reported sales that missed analyst estimates after weaker-than-expected volumes hurt results. The key measure of organic ...

Known for brands like Tylenol and Listerine, it focuses on maintaining its competitive edge through strong brand recognition ...

Consumer health company Kenvue forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a stronger ...

Rosuvastatin has possible interactions with alcohol, some other drugs, and certain supplements. Examples include antacids ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

(Reuters) - Consumer health company Kenvue forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a ...

Activist investment firm Starboard Value has launched a proxy battle with pharmacy supplier Kenvue, running a slate of four board nominees including Starboard head Jeff Smith.

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.